NCT05810402Recruiting
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
Liver Cancer and Immunotherapy : Clinical Relevance of LIquid BioPSY
Source: ClinicalTrials.gov · Last updated 10 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy. The main questions it aims to answer are: * Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency? * Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients? Participants blood will be collected at several time points.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 30 Mar 2023
- Start date
- 28 Jun 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05810402
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 28 Jun 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Administration of a previous systemic anti-tumor treatment (immunotherapy or chemotherapy or targeted therapy)
- No personal history of neoplasia in the previous 5 years
Other illness
- No personal history of systemic inflammatory diseases
Age
- Persons of full age who are protected or unable to give their consent according to article L1121-8 of the CSP;
Other
- No immunosuppressive treatment or treatment that could modify immunity (anti-TNF...)
- No affiliation or non-beneficiary of a Social Security system;
- Vulnerable persons according to article L1121-6 of the CSP ;
- Pregnant or breastfeeding women according to article L1121-5 of the CSP.
- Non-inclusion due to follow-up difficulties (transfer, insufficient motivation, poor compliance, priority associated pathology in care, etc.)
Who the study is looking for
- Patients of at least 18 years old,
- Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic therapy,
- The diagnosis of HCC is established according to imaging criteria (LI-RADSv2018 criteria) or after histological evidence,
- Advanced HCC defined by BCLC stages B and C,
- Patients with oral consent.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Montpellier Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.